Why the study?
Carnosine has been suggested to reduce ASCVD risk factors in patients with prediabetes and T2DM, but human data are scarce.
Does carnosine supplementation improve vascular and metabolic outcomes in patients with prediabetes and T2DM?
Does carnosine supplementation improve vascular and metabolic outcomes in patients with prediabetes and T2DM?
Carnosine supplementation (2 g/day for 14 weeks) does not improve cardiovascular or cardiometabolic risk factors in patients with prediabetes and T2DM.
No takes yet. Share an insight, caveat, or question.
Carnosine supplementation confers no vascular or cardiometabolic benefit in prediabetes and T2DM; confirms lack of efficacy and should not alter practice.
Saadati et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: